Investigate / BDX
Understand BECTON DICKINSON & CO
After the Waters spin-off, can the remaining BD segments execute the stated compete, innovate and deliver strategy despite tariff, supply chain and China procurement pressures?
Snapshot reviewed 2026-10-02. Source published 2026-08-06. No account needed.
AI-assisted synthesis of selected public filings, checked against the cited excerpts. Not a complete analysis.
This is a research starting point, not a buy/sell recommendation or a current valuation. New developments after these sources are not incorporated automatically.
Your research workspace / BDX
Ask better questions. Keep the evidence.
Explore the available sources for BECTON DICKINSON & CO, then keep what deserves another look.
01 Investor activity
Who reports owning BDX?
9 tracked reported owners. Disclosures are delayed and may describe different quarters—not live holdings or stated motives.
02 Business evidence
Reported evidence
What does the company do?
BD develops, makes and sells medical supplies, devices and related products used by healthcare institutions, physicians, laboratories, the pharmaceutical industry and the general public.
Latticework interpretation
What could support the case?
If the New BD strategy succeeds, elevated commercial capabilities could help BD gain share in the fastest growing areas of the medical technology market.
Latticework interpretation
What could break the case?
Tariffs may continue to raise operating expense into later years, with limited mitigation opportunities for products or components imported across the global supply chain, which could pressure results.
03 Questions to investigate
Open saved takeaways →Read the full company brief
1. Understand the business
BD develops, makes and sells medical supplies, devices and related products used by healthcare institutions, physicians, laboratories, the pharmaceutical industry and the general public.
Source: Latest filing · business description ↗2. What the reported results show
Latest source: 10-Q, reporting period ended 2026-06-30. Selected reported US-GAAP/USD comparisons. The period and basis of each measure are shown separately; year-to-date cash flow is not a quarterly figure. Missing comparisons are collection gaps, not evidence that a company has no revenue or earnings.
| Measure | Current | Prior year |
|---|---|---|
| Revenue ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $4,983m | $4,726m |
| Operating income ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $663m | $739m |
| Net income ↗Quarter: 2026-04-01–2026-06-30; prior 2025-04-01–2025-06-30Both values reported in the current filing. | $377m | $574m |
Comparison caveat: After the Waters spin-off, displayed revenue and operating income cover continuing operations, while net income includes discontinued operations. Prior periods are recast; inspect both scopes.
10-Q · latest checked financial statements and discussion ↗3. The investment debate
Latticework interpretation of the reported results—not the stated motives of any investor.
What could support the case
If the New BD strategy succeeds, elevated commercial capabilities could help BD gain share in the fastest growing areas of the medical technology market.
Supporting filing ↗The strongest caution
Tariffs may continue to raise operating expense into later years, with limited mitigation opportunities for products or components imported across the global supply chain, which could pressure results.
Caution evidence ↗An interesting business is not necessarily an attractive investment at today's price. Price, dilution, financing terms and a valuation range still need investigation.
Inspect the evidence behind both sides ↗4. Three questions worth investigating
Use these to guide your research, not as conclusions that have already been proved.
How exposed is BD to tariff costs?
Starting evidence: Tariffs are expected to adversely affect operating expense, with limited mitigation opportunities for imported products and components.
Investigate next: Review how much tariff cost comes from imported components and which mitigation steps management has described in recent filings.
Read the supporting filing ↗How much does China procurement reform affect results?
Starting evidence: China market dynamics such as volume-based procurement and healthcare cost containment have adversely affected results and may continue to do so.
Investigate next: Look for segment or regional disclosures showing which product lines face volume-based procurement and how pricing and volumes have responded.
Read the supporting filing ↗Is the post-spin-off segment structure delivering on strategy?
Starting evidence: After separating Life Sciences, BD reports Medical Essentials, Connected Care, BioPharma Systems and Interventional, with prior-period segment amounts recast.
Investigate next: Compare recast segment results and management commentary on share gains, pipeline execution and cash flow generation across the four segments.
Read the supporting filing ↗5. Decide what to do next
Worth another look? Save this company and return to the evidence. Writing a private view is optional. You do not need to decide whether to invest today.
Save is on this device. Recording a private view requires sign-in and an explicit save. Neither action subscribes you to email or automatically evaluates your thesis.